<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00871806</url>
  </required_header>
  <id_info>
    <org_study_id>A1601122</org_study_id>
    <nct_id>NCT00871806</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Two Eletriptan Oral Formulations Given With and Without Water and the Commercial Tablet Formulation Given With Water</brief_title>
  <official_title>Phase 1, Open-Label, Randomized, Single-Dose, 5-Way Crossover Pilot Bioavailability Study Comparing Eletriptan Oral Disintegrating Tablet Formulations A And B Administered With Or Without Water To RelpaxÂ® Commercial Tablets Administered With Water</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate whether the blood concentrations of eletriptan administered using two
      test formulations of oral disintegrating tablets are comparable to those observed with the
      standard commercial tablet.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eletriptan area under the concentration time curve (AUC) and peak concentration (Cmax)</measure>
    <time_frame>24 hr</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of peak eletriptan concentrations (Tmax), half life</measure>
    <time_frame>24 hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability and safety of treatments assessed by adverse events, vital signs, clinical lab tests</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Eletriptan commercial tablet with water</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eletriptan commercial tablet given with water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eletriptan oral disintegrating tablet (ODT) #1 without water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral disintegrating tablet formulation #1 without water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral disintegrating tablet formulation (ODT) #2 without water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral disintegrating tablet formulation #2 without water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral disintegrating tablet formulation (ODT) #1 with water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral disintegrating tablet formulation (ODT) #1 with water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral disintegrating tablet formulation (ODT) #2 with water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral disintegrating tablet formulation (ODT) #2 with water</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Commercial tablet with water</intervention_name>
    <description>40 mg tablet, given once to each subject</description>
    <arm_group_label>Eletriptan commercial tablet with water</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ODT #1 without water</intervention_name>
    <description>40 mg tablet given once to each subject</description>
    <arm_group_label>Eletriptan oral disintegrating tablet (ODT) #1 without water</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ODT #2 without water</intervention_name>
    <description>40 mg tablet given once to each subject</description>
    <arm_group_label>Oral disintegrating tablet formulation (ODT) #2 without water</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ODT #1 with water</intervention_name>
    <description>40 mg tablet given once to each subject</description>
    <arm_group_label>Oral disintegrating tablet formulation (ODT) #1 with water</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ODT #2 with water</intervention_name>
    <description>40 mg tablet given once to each subject</description>
    <arm_group_label>Oral disintegrating tablet formulation (ODT) #2 with water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects

          -  No CYP3A4 inhibitors

        Exclusion Criteria:

          -  Clinically significant disease in any organ system

          -  Positive urine drug screen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>188770</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1601122&amp;StudyName=Pharmacokinetics%20of%20two%20eletriptan%20oral%20formulations%20%20given%20with%20and%20without%20water%20and%20the%20commercial%20tablet%20formulation%20given%20with%20wate</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>March 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2009</study_first_posted>
  <last_update_submitted>April 22, 2010</last_update_submitted>
  <last_update_submitted_qc>April 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>eletriptan</keyword>
  <keyword>bioavailability</keyword>
  <keyword>oral disintegrating tablet</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eletriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

